Enrolling 55% of Total Participants for a Phase 3 Neurology Trial

Science 37 was the top enrolling site, enrolling 55% of total study participants and achieving a 98% visit completion rate. While each of the participating traditional brick-and-mortar sites averaged less than 1 patient enrolled, Science 37 enrolled 33 patients. Science 37 also contributed 77% of the required completers for interim analysis.